Safer treatment products in Nepal

NHS continues to ask government to fund virus-inactivated factor and reliable testing nationwide — because product choice is a safety decision.

Why product type matters

Clotting factor concentrates made from pooled human plasma carry infection risk if not properly screened and virus-inactivated. Recombinant products reduce but do not eliminate all risks; no medicine is careless-proof without records.

Cryoprecipitate and fresh frozen plasma play roles in some settings but are not interchangeable with factor VIII concentrate for haemophilia A on demand or prophylaxis.

Humanitarian aid and national supply

The World Federation of Hemophilia has arranged humanitarian shipments to Nepal including standard and sometimes extended half-life or non-factor products. Shipments change year to year and patient by patient.

Aid fills gaps; it does not replace provincial budgets for sustained pharmacy stock. NHS argues both must exist.

What families should insist on in writing

Product name, batch number, expiry, storage temperature, and dose for every infusion. If the centre switches brands, ask why and how dose converts.

Keep copies in the folder you carry to every appointment. Those papers matter if you ever need infection testing or switch hospitals.

Advocacy link

The 11 March 2024 provincial meeting explicitly included the supply question: what provinces fund, not only what posters say.

Send your district supply story to nepalhemo@gmail.com so the next government meeting has evidence from outside Kathmandu.

This page is general information from Nepal Hemophilia Society. It is not a diagnosis or a treatment plan. A bleed, a head injury, or bleeding after an accident needs urgent hospital care. Ask your treatment centre before you change any treatment.